Developmental Psychopharmacology (R21)

The summary for the Developmental Psychopharmacology (R21) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Developmental Psychopharmacology (R21)
	CFDA Number:	93.242
	CFDA Description:	Mental Health Research Grants
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health Income Security and Social Services
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-07-222
	Document Type:	Modification to Previous Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Feb 21, 2007
	Creation Date:	Feb 25, 2009
	Original Closing Date for Applications:	Multiple Receipt Dates - See Link to Full Announcement for details.
	Current Closing Date for Applications:	Feb 25, 2009 Multiple Receipt Dates - See Link to Full Announcement for details.
	Archive Date:	Mar 25, 2009
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Grant Description: -Purpose. The purpose of this Funding Opportunity Announcement (FOA) is to request research applications to examine the neurobiological impact of psychotherapeutic medications upon the immature brain, with particular emphasis upon mapping the precise developmental profile of physiological response to psychotropic agents used in the treatment of mental disorders in children. Appropriate research includes studies in model systems, including animals, and in human populations. -Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-07-084, that solicits applications under the R01 mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon availability of funds and the submission of a sufficient number of meritorious applications.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/pa-07-222.html
Grant Announcement Contact: NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R21); • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R03); • Advancing the Impact of Effective HIV/AIDS Prevention and Treatment Interventions (R03); • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R34); • Advancing the Impact of Effective HIV/AIDS Prevention and Treatment Interventions (R34); • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R42]); • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44]); • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44]); • Pharmacologic Agents and Drugs for Mental Disorders (STTR [R41/R42]); • Solicitation of Assays for High Throughput Screening (HTS) in the Molecular Libraries Screening Cent...